Basel, Switzerland and Berlin, Germany, 19 April 2011 – Lonza and ORGANOBALANCE today
announced the signing of a worldwide exclusive license agreement in which Lonza will develop,
produce and commercialize products containing a probiotic Lactobacillus strain. Developed by
ORGANOBALANCE GmbH, the probiotic strain acts against Helicobacter pylori (H. pylori).
Research shows that H. pylori has been implicated as a common cause of peptic ulcers and
gastritis.

Currently, about 50 percent of the global population is infected with H. pylori (Source: Czinn SJ. J
Pediatr. 2005 Mar;146 (3 Suppl):S21-6.). However, this new probiotic strain demonstrates great
potential in helping to maintain a balanced H. pylori concentration. Utilizing a unique patent-
protected mode of action, Lactobacillus anti-H. pylori binds to H. pylori in the stomach, thus
creating large aggregates, which are subsequently flushed out of the stomach and excreted.

“This agreement with ORGANOBALANCE creates a basis for Lonza to enter the probiotic market
-a market with vast growth potential- with a unique ingredient,” said Roman Quinter, Senior Vice
President and Head of Nutrition Ingredients business for Lonza. “Lonza is a global leader in the
manufacturing of intermediates and API’s for the pharmaceutical industry through biotechnology
and fermentation. Integrating the Lactobacillus anti-H. pylori strain into our nutrition ingredient
portfolio provides an opportunity to leverage our strong biotech expertise and knowledge to
provide a highly effective product to the nutrition landscape.“

“As the leader in the development of innovative probiotic strains, we regard this agreement with
Lonza as a further recognition of ORGANOBALANCE’s strategy, our expertise, and our
innovative capacity,” said Prof. Dr. Christine Lang, CEO of ORGANOBALANCE GmbH. “We
highly appreciate Lonza’s dedication to lead our development into great success on the nutrition
marketplace.”

About Lonza

Lonza is one of the world's leading suppliers to the pharmaceutical, healthcare and life science
industries. Products and services span its customers’ needs from research to final product
manufacture. It is the global leader in the production and support of active pharmaceutical
ingredients both chemically as well as biotechnologically. Biopharmaceuticals are one of the key
growth drivers of the pharmaceutical and biotechnology industries. Lonza has strong capabilities
in large and small molecules, peptides, amino acids and niche bioproducts which play an
important role in the development of novel medicines and healthcare products. In addition, Lonza
is a leader in cell-based research, endotoxin detection and cell therapy manufacturing.
Furthermore, the company is a leading provider of value chemical and biotech ingredients to the
nutrition, hygiene, preservation, agro and personal care markets.

Lonza Group Ltd

Muenchensteinerstrasse 38

4002 Basel, Switzerland

www.lonza.com

ORGANOBALANCE GmbH

Gustav-Meyer-Allee 25

13355 Berlin, Germany

www.organobalance.com

Lonza is headquartered in Basel, Switzerland and is listed on the SIX Swiss Exchange. In 2010,
the company had sales of CHF 2.680 billion. Further information can be found at www.lonza.com.

About ORGANOBALANCE

ORGANOBALANCE GmbH is a company specialising in strain development and microbiological
screening, tapping the potential of beneficial microorganisms, known as specific probiotic
cultures, in order to balance out the microflora and restore the microbial equilibrium in a natural
way. In close cooperation with renowned industry partners, ORGANOBALANCE GmbH develops
new biological products in the fields of pharmaceutics, preventive health care, nutrition and
cosmetics. In its development activities the company draws on its own collection of more than
8000 microorganisms suitable for use in foodstuffs as well as its own OASSYS® screening
systems. ORGANOBALANCE was founded in 2001 and is based in Berlin, Germany. More
information can be found at www.organobalance.com.